CENTENE CORPORATION ANNOUNCES 2024 GUIDANCE

Rhea-AI Summary

Centene Corporation (CNC) increases 2024 adjusted diluted EPS guidance to over $6.70 and authorizes a $4.0 billion increase to stock repurchase program. Reaffirms 2023 adjusted diluted EPS guidance of at least $6.60. The company's 2024 fiscal year guidance includes total revenues of $142.5 billion to $145.5 billion, premium and service revenues of $132.0 billion to $135.0 billion, GAAP diluted EPS of greater than $5.61, and diluted shares outstanding of 522.2 million to 525.2 million.

Positive

• Centene increases 2024 adjusted diluted EPS guidance to over $6.70
• Reaffirms 2023 adjusted diluted EPS guidance of at least $6.60
• Board authorizes a $4.0 billion increase to stock repurchase program

Negative

• None.

• 2024 adjusted diluted EPS of greater than $6.70.
• Board authorizes $4.0 billion increase to stock repurchase program.
• Reaffirms 2023 adjusted diluted EPS guidance of at least $6.60.

ST. LOUIS, Dec. 12, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC) ("the Company") today will host its investor day to outline its 2024 financial guidance as well as provide updates on its long-term strategic plan, designed to deliver long-term shareholder value.

"We continue to execute against our strategic plan, positioning Centene to deliver strong, long-term earnings growth and create meaningful shareholder value. Looking to the year ahead, we see the opportunity to provide access to high-quality health care for more Americans by working every day to make healthcare affordable. Today, we are increasing our 2024 adjusted diluted EPS outlook to "greater than $6.70," indicative of positive operational momentum and strong execution against our plan. While there is still work to do, we are proud of the significant progress made this year and are energized to continue demonstrating results in 2024," said Chief Executive Officer of Centene, Sarah M. London.

 For its 2024 fiscal year, the Company's guidance is as follows:

• Total revenues of $142.5 billion to $145.5 billion.
• Premium and service revenues of $132.0 billion to $135.0 billion.
• GAAP diluted earnings per share (EPS) of greater than $5.61.
• Adjusted diluted EPS of greater than $6.70.
• Health benefits ratio of 87.3% to 87.9%.
• Selling, general and administrative (SG&A) expense ratio of 8.4% to 9.0%.
• Adjusted SG&A expense ratio of 8.4% to 9.0%.
• Effective tax rate of 24.3% to 25.3%.
• Adjusted effective tax rate of 24.1% to 25.1%.
• Diluted shares outstanding of 522.2 million to 525.2 million.

In addition, the Company also announced today that its Board of Directors has authorized a $4.0 billion increase to the Company's existing stock repurchase program. The increase is in addition to the approximately $1.2 billion remaining under the previously authorized program.

The Company reaffirms its 2023 premium and service revenues in the previously announced range of $137.5 billion to $139.5 billion, HBR guidance in the previously announced range of 87.1% to 87.7% and adjusted diluted EPS guidance of at least $6.60. Full year 2023 earnings will be reported on February 6, 2024, at 6:00 a.m. (Eastern Time), with a conference call at 8:30 a.m. (Eastern Time).

Investor Meeting

Centene Corporation will host an investor day today. Sarah London, Chief Executive Officer, and other members of the Centene management team, will host the event, which will also be webcast live from the New York Stock Exchange. The event will begin promptly at 8:30 a.m. EST (Eastern Standard Time).

In-person attendance is by invitation only. As previously announced, all others are invited to participate in the investor meeting via live webcast on the Company's website at www.centene.com, under the Investors section, or directly via the following link at https://event.webcasts.com/starthere.jsp?ei=1638571&tp_key=cb2fedd0a6.

Non-GAAP Financial Presentation

The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

The Company believes the presentation of non-GAAP financial measures that excludes amortization of acquired intangible assets, acquisition and divestiture related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's core performance over time.

The Company references 2024 adjusted effective tax rate guidance, which excludes acquisition and divestiture related expenses and amortization of acquired intangible assets, as well as other items. The Company references 2024 adjusted SG&A expense ratio guidance, which excludes estimated acquisition and divestiture related expenses of approximately $55 million and estimated severance costs due to a restructuring of approximately $10 million. These items cannot be reconciled to the most directly comparable GAAP financial measure without unreasonable effort. The Company is unable to provide a reconciliation of its 2023 adjusted diluted EPS guidance range to the most directly comparable GAAP financial measure without unreasonable effort. The 2023 adjusted diluted EPS guidance excludes the items we typically adjust on a non-GAAP basis.

The table below provides a reconciliation of the Company's 2024 adjusted diluted EPS guidance:

	Annual Guidance December 31, 2024
GAAP diluted EPS	> $5.61
Amortization of acquired intangible assets	~$1.32
Acquisition and divestiture related expenses	~$0.10
Other adjustments (1)	~$0.02
Income tax effects of adjustments (2)	~$(0.35)
Adjusted diluted EPS	> $6.70
(1)  Other adjustments include an estimated $0.02 ($0.01 after-tax) of severance costs due to a restructuring. (2)  The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment.

About Centene Corporation

Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities and government partners.

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com.

Forward-Looking Statements

All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "guidance," "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue," and other similar words or expressions (and the negative thereof). Centene (the Company, our, or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, value creation strategy, competition, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables, and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound including but not limited to any impacts resulting from Medicaid redeterminations; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates; competition, including our ability to reprocure our contracts and grow organically; the timing and extent of benefits from our value creation strategy, including the possibility that the benefits received may be lower than expected, may not occur, or will not be realized within the expected time periods; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third parties; impairments to real estate, investments, goodwill, and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; changes in healthcare practices, new technologies, and advances in medicine; increased healthcare costs; inflation; changes in economic, political, or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder; tax matters; disasters or major epidemics; changes in expected contract start dates; changes in provider, state, federal, foreign, and other contracts and delays in the timing of regulatory approval of contracts, including due to protests; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare, TRICARE, or other customers); the difficulty of predicting the timing or outcome of legal or regulatory proceedings or matters, including, but not limited to, our ability to resolve claims and/or allegations made by states with regard to past practices, including at Centene Pharmacy Services (formerly Envolve Pharmacy Solutions, Inc. (Envolve)), as our pharmacy benefits manager (PBM) subsidiary, within the reserve estimate we previously recorded and on other acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought by states, the federal government or shareholder litigants, or government investigations; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions, including due to the timing of regulatory approval for the pending sale of Circle Health Group (Circle Health); losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of the credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us; foreign currency fluctuations; and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs. The guidance in this press release is only effective as of the date given, December 12, 2023, and will not be updated or affirmed unless and until we publicly announce updated or affirmed guidance.

View original content:https://www.prnewswire.com/news-releases/centene-corporation-announces-2024-guidance-302011961.html

SOURCE Centene Corporation

FAQ

What is Centene Corporation's ticker symbol?

Centene Corporation's ticker symbol is CNC.

What is Centene Corporation's 2024 adjusted diluted EPS guidance?

Centene Corporation's 2024 adjusted diluted EPS guidance is over $6.70.

What is Centene Corporation's 2023 adjusted diluted EPS guidance?

Centene Corporation's 2023 adjusted diluted EPS guidance is at least $6.60.

What is the total revenue range for Centene Corporation's 2024 fiscal year?

Centene Corporation's 2024 fiscal year total revenue range is $142.5 billion to $145.5 billion.

What is the diluted shares outstanding range for Centene Corporation's 2024 fiscal year?

Centene Corporation's 2024 fiscal year diluted shares outstanding range is 522.2 million to 525.2 million.

What is the increase in Centene Corporation's stock repurchase program?

Centene Corporation has authorized a $4.0 billion increase to its stock repurchase program.

When will Centene Corporation report its full year 2023 earnings?

Centene Corporation will report its full year 2023 earnings on February 6, 2024, at 6:00 a.m. (Eastern Time).